NRx Logo
  • Our Company
  • Our Therapeutic Focus
    • Our Focus on the Brain
    • Bipolar Depression & Suicidality
    • Post-Traumatic Stress Disorder
  • Our Science
    • Our Clinical Approach
    • NRX-100/NRX-101
    • Mechanism of Action
    • NMDA & 5HT2A receptors
    • Publications & Literature
  • Pipeline
  • Investors / Media
  • Investor Relations
  • Presentation
  • Clinical Trials
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Analyst Coverage
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Analyst Coverage
  • IR Calendar
  • Email Alerts
Jan 31, 2022 7:59am EST

NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules

Jan 27, 2022 6:51am EST

NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant

Jan 26, 2022 6:51am EST

NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge

Jan 18, 2022 6:48am EST

NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments

Jan 14, 2022 2:34pm EST

NRx Responds to Relief’s Allegations of January 14, 2022

Jan 12, 2022 5:48pm EST

NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics

Jan 11, 2022 7:54am EST

NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant

Jan 07, 2022 5:49pm EST

NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine

Jan 07, 2022 6:48am EST

NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual Conference

Jan 05, 2022 6:48am EST

NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 16
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
NRx
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Careers
  • Contact Us
  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use
  • © 2022 NRx Pharmaceuticals, Inc.

  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin